Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

安进赌输了。 在炎症微环境中，APC表面OX40L表达上调，进一步放大抗原特异性T细胞反应及促炎细胞因子分泌。 在多种炎症性和自身免疫性疾病中，OX40L和OX40存在表达升高的现象，如特应性皮炎、哮喘、多发性硬化症、类风 湿性关节炎、炎症性肠病、克罗恩病和系统性红斑狼疮。鉴于其在T细胞激活中的上游调控地位，阻断该相互作用可 有效抑制T细胞相关病理性免疫应答，由此催生了OX40/OX40L靶向疗法的研发热潮。 而rocatinlimab则是该领域的领跑者之一，且早期结果惊艳。2022年12月，安进公布的rocatinlimab在特应性皮炎中的二 期数据显示，接受4种不同剂量rocatinlimab治疗的患者组的EASI评分与安慰剂组相比，均获得统计学显著改善。 600mg每两周（Q2W）组EASI降低57.4%，300mgQ2W组降低61.1%，安慰剂组降低15%（所有剂量组与安慰剂相比， P<0.001）。 2021年6月，安进以4亿美元首付款、高至8.5亿美元的潜在里程碑付款以及未来销售分成，从日本制药企业协和麒麟获 得OX40单抗rocatinlimab在日本外的全球权益。 引进之后，安进火力全开，推进 ...

Group 1 - Sanofi SA is considered one of the best cheap stocks to buy for 2026 according to Citi Research, which initiated coverage of six large European pharmaceutical stocks including Sanofi [1] - Citi assigned Sanofi a Neutral rating with a price target of €85, indicating concerns about the company's drug development progress and a weakened long-term growth outlook due to pipeline setbacks [2][3] - The current valuation of Sanofi is approximately 10 times expected 2026 earnings, reflecting the setbacks in its pipeline, and the market is unlikely to reward the stock with a higher multiple without tangible evidence of improvement [3] Group 2 - Sanofi reported positive results for its experimental medicine amlitelimab in Phase 3 clinical studies for moderate-to-severe atopic dermatitis, with data coming from two major global trials, SHORE and COAST 2 [4] - The results from the studies indicate that amlitelimab was generally well tolerated, with side effects consistent with previous findings [4] - Sanofi operates in various segments including specialty care, vaccines, and general medicines, focusing on the research, development, manufacturing, and marketing of pharmaceutical products [5]

智通财经APP获悉，尽管法国政治动荡一度被市场视为对本土企业的最大威胁，但出人意料的是，国内 导向型股票反而成为大赢家。与此同时，出口型企业则因美国关税威胁和欧元走强等因素而步履维艰。 CAC40指数的一大短板在于，其成分股的本土营收占比仅为16%，这一特征不仅令投资者却步，也使得 该指数与欧元区其他市场的估值差距再度拉大，达到了疫情后初期之外的历史高位水平。 自2024年6月法国总统马克龙宣布提前举行大选以来，高盛编制的一篮子与法国经济相关的行业指数涨 幅已超30%，不仅大幅跑赢法国蓝筹股CAC40指数2.8%的涨幅，表现也优于欧洲斯托克600指数。 马克龙的大选决定引发了持续的政治不确定性，法国在不到两年时间里换了四位总理，彼时几乎无人看 好本土股表现。市场曾普遍认为，银行、公用事业和电信板块可能会落后于大盘，而全球经济的复苏韧 性则会利好LVMH(LVMUY.US)、赛诺菲(SNY.US)等出口型企业。然而，同期高盛编制的海外业务相关 板块指数却下跌了10%。 巴克莱银行策略师Emmanuel Cau表示："原本预期欧洲出口股将在2026年反弹的投资者，或许需要重新 审慎规划投资策略。市场此前预计资金会 ...

Core Insights - The Travel Vaccines Market is projected to grow from USD 5.22 billion in 2025 to USD 10.69 billion by 2033, with a CAGR of 9.37% from 2026 to 2033, driven by international tourism, business travel, and increased awareness of vaccine-preventable diseases [1][6]. Market Size and Forecast - The U.S. Travel Vaccines Market is expected to grow from USD 1.42 billion in 2025 to USD 2.49 billion by 2033, at a CAGR of 7.32%, supported by outbound travel to emerging economies and increased vaccination services [4]. - The overall Travel Vaccines Market is anticipated to expand significantly, with a base year of 2025 and a forecast period from 2026 to 2033 [6]. Government Initiatives and Immunization Programs - Public health agencies globally are promoting vaccination to prevent diseases like yellow fever and hepatitis among travelers, enhancing vaccine uptake through national immunization policies and partnerships with travel agencies [5]. Market Segmentation Analysis - By Disease Type: Influenza dominates the market with a 38.50% share in 2025, expected to rise to 41.50% by 2033, while the "others" category is the fastest-growing segment, increasing from 10.38% to 12.63% [9]. - By Booking Channel: Online booking leads with a 59.75% market share in 2025, projected to grow to 70.25% by 2033, reflecting the trend towards digital healthcare solutions [10]. - By Tourist Type: Domestic travelers hold 61.13% of the market in 2025, but their share is expected to decrease to 55.88% by 2033, while international travelers will grow from 38.88% to 44.13% [11]. Regional Insights - North America holds the largest share of the Travel Vaccines Market at 41.13% in 2025, driven by strong healthcare systems and vaccination programs [15]. - The Asia Pacific region is the fastest-growing market, with a CAGR of 2.57%, fueled by increased travel and improved healthcare infrastructure [16]. Competitive Landscape - Major companies in the Travel Vaccines Market include GlaxoSmithKline, Merck & Co., Sanofi, and Pfizer, among others, indicating a competitive environment with significant R&D investments [13].

好的，各位投资人，晚上好，然后欢迎参加我们的医药每周谈第 236 期，关于 GP MOOC 2026 的海外公司的一个进展。然后我是中银建投医药分析师徐颖翔。然后就是关于整个 Gilead 海外公司的一个情况吧。我们可以看得出来，在整个基于摩根这个期间的话，海外 的药企主要就是在一个专利悬崖的一个压力下面，是加速转型与和与技术兑现。大部分跨 国药企的话，是通过一个大规模的 BD 和并购来平滑自己重磅产品专利的到期的一个销售 冲击。包括默沙东规划 700 亿美元的一个新的产品组合，BMS 的话这几年也完成了 300 亿美元的一个并购交易，阿斯利康的话也是目标在 2030 年能够实现一个 800 亿美元的一 个营收。 因此这几年的话，整个受并购与 BD 还是各家跨国药企最重要的一个战略布局的一个方向， 主要也就是为了应对专利悬崖，同时聚焦高确定性的资产，以及技术平台的一个补强。另 一方面的话，也是整个 AI，从工具也上升到了一个制药的一个核心生产力。成为整个制药 行业的一个核心的驱动，驱动力之一。多家跨国药企，包括礼来、阿斯利康、赛诺菲，都 在 GD Morgan 期间。通过与英伟达以及各种其他的 AI 公司达成 ...

机构：国海证券 研究员：曹泽运/万鹏辉 投资要点: 持续达成研发合作，AI 制药能力不断被认可2021 年至今，公司已于多家国内外龙头药企达成研发合 作，其中2022 年跟赛诺菲达成最高12 亿美元+特许权使用费合作，2025 年跟礼来达成超1 亿美元+特许 权使用费合作，2026 年与施维雅达成多年期抗肿瘤药物研发合作，协议总金额高达8.88 亿美元。多家 国内外龙头药企陆续跟公司达成AI 平台研发合作，公司AI 平台研发能力不断被认可。 已有多款自研管线对外授权2023 年至今，公司已经完成3 笔对外自主研发管线的对外授权，分别为： 2023 年对EXELIXIS 授权USP1 靶点药物，总金额接近10 亿美元，其中首付款8000 万美元；2023 年对 Menarini 授权KAT6 小分子，总金额超过5 亿美元，其中首付款1200 万美元；2024 年继续对Menarini 授 权，总金额超过5.5亿美元，首付款2000 万美元，2025 年12 月授权太景PHD 抑制剂ISM4808 大中华区 开发、商业化和再许可权力，交易总额达数千万美元，以上均包含特许权使用费。2026 年1 月，对衡泰 生物授 ...

新兴产业未来产业集中落地 从领域上看，100个重大科技创新及现代化产业项目的投资比重是最高的，当年计划投资达到1428亿 元。 科创+产业： 这100个项目中首先包括加快高水平科技自立自强的一批科研基础设施。市发改委相关负责人说，今年 本市将统筹科技基础设施平台建设，着力提升"三城一区"主平台发展能级，深化农业中关村建设，安排 11个重大科研基础设施项目，包括北京理工大学创新平台集群实验室项目、北京（平谷）农业微生物国 际创新研究院等。 50个新兴产业和未来产业项目也纳入今年的计划。其中，有人工智能创新街区文化智境等项目，将构建 集成电路和人工智能产业创新高地；有北汽享界生产线技术改造等项目，增强新能源汽车产业竞争力； 还有赛诺菲生物制剂原料药产业化、中关村（朝阳）数字医疗产业园二期等项目，提质升级医药健康产 业；更有航天火箭智能感知产业基地等项目，壮大空天技术产业…… 本报记者 曹政 昨天，2026年北京市重点工程计划发布。市发改委介绍，今年本市将持续发挥"3个100"市重点工程的示 范引领作用，集中推进100个重大科技创新及现代化产业项目、100个重大基础设施项目和100个重大民 生改善项目，以重大项目带 ...

Core Viewpoint - Sanofi has violated the UK pharmaceutical code of practice by making unsubstantiated claims regarding the effectiveness of its Beyfortus compared to Pfizer's RSV vaccine [1] Group 1: Company Actions - Sanofi's claims about Beyfortus being more effective than Pfizer's RSV vaccine have been deemed unsubstantiated by the industry's self-regulatory body [1] - The breach of the UK pharma code of practice indicates potential regulatory scrutiny and reputational risks for Sanofi [1] Group 2: Industry Implications - The incident highlights the importance of adhering to industry standards and regulations in pharmaceutical marketing [1] - This breach may lead to increased scrutiny of marketing practices across the pharmaceutical industry, particularly regarding comparative effectiveness claims [1]

Group 1: SpaceX and xAI - SpaceX and xAI are reportedly in advanced discussions for a potential merger or strategic deal, with an announcement possible as soon as this week [2][11] - The merger would combine SpaceX's aerospace manufacturing and space transportation capabilities with xAI's focus on artificial intelligence, potentially enhancing SpaceX's operations and future projects [3][11] Group 2: Verizon - Verizon is in the process of identifying candidates to succeed Sowmyanarayan Sampath, the current head of its consumer division, indicating a potential leadership change [4][5][11] - The leadership change in such a critical division could signal a strategic shift for Verizon as it navigates a competitive telecom landscape [5][11] Group 3: Ford - The National Highway Traffic Safety Administration (NHTSA) has initiated an engineering analysis into approximately 1.3 million Ford F-150 vehicles due to reports of unintended transmission downshifts and rear wheel lock-ups [6][11] - This investigation aims to determine the scope and severity of the alleged defect, which could lead to a significant recall impacting Ford's financial performance and brand reputation [7][11] Group 4: Sanofi - Sanofi has received a reprimand from a UK regulator for making misleading claims about its RSV vaccine and for disparaging Pfizer's competing product [8][9][11] - This regulatory action underscores the intense competition and scrutiny within the pharmaceutical industry, particularly regarding new and high-demand vaccines [9][11]